Devonian Health Group (CVE:GSD) Trading Up 11.5% – Time to Buy?

Devonian Health Group Inc. (CVE:GSD) shares rose 11.5% during mid-day trading on Friday . The stock traded as high as C$11.15 and last traded at C$11.15. Approximately 2,600 shares changed hands during trading, an increase of 120% from the average daily volume of 1,184 shares. The stock had previously closed at C$10.00.

Devonian Health Group Stock Up 11.5%

The company has a debt-to-equity ratio of 16.36, a current ratio of 1.07 and a quick ratio of 7.82. The stock has a market capitalization of C$31.01 million, a PE ratio of -3.21 and a beta of 1.09. The company has a 50 day moving average price of C$11.80 and a 200-day moving average price of C$11.70.

About Devonian Health Group

Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics. In addition, the company acquires drug and health product licenses; and distributes pharmaceutical products.